Total Payments
$760,521
2024 Payments
$41,912
Companies
15
Transactions
613
Medicare Patients
5,685
Medicare Billing
$707,666
Payment Breakdown by Category
Other$579,947 (76.3%)
Travel$76,640 (10.1%)
Consulting$73,859 (9.7%)
Research$15,044 (2.0%)
Food & Beverage$14,811 (1.9%)
Education$220.32 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $579,947 | 182 | 76.3% |
| Travel and Lodging | $76,640 | 202 | 10.1% |
| Consulting Fee | $73,859 | 23 | 9.7% |
| Unspecified | $15,044 | 8 | 2.0% |
| Food and Beverage | $14,811 | 189 | 1.9% |
| Education | $220.32 | 9 | 0.0% |
Payments by Type
General
$745,477
605 transactions
Research
$15,044
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $291,769 | 212 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $203,047 | 180 | $0 (2019) |
| Esperion Therapeutics, Inc. | $137,032 | 111 | $0 (2024) |
| Amarin Pharma Inc. | $47,549 | 32 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $34,335 | 25 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $28,889 | 13 | $0 (2024) |
| Amgen Inc. | $13,100 | 27 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,437 | 3 | $0 (2021) |
| Alexion Pharmaceuticals, Inc. | $1,960 | 1 | $0 (2020) |
| IDORSIA PHARMACEUTICALS US INC | $120.82 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41,912 | 58 | Esperion Therapeutics, Inc. ($25,820) |
| 2023 | $11,277 | 17 | Novartis Pharmaceuticals Corporation ($8,921) |
| 2022 | $13,841 | 17 | Esperion Therapeutics, Inc. ($11,151) |
| 2021 | $109,251 | 75 | Esperion Therapeutics, Inc. ($79,290) |
| 2020 | $50,021 | 28 | Esperion Therapeutics, Inc. ($18,800) |
| 2019 | $150,548 | 136 | SANOFI-AVENTIS U.S. LLC ($101,917) |
| 2018 | $196,796 | 132 | SANOFI-AVENTIS U.S. LLC ($94,940) |
| 2017 | $186,875 | 150 | SANOFI-AVENTIS U.S. LLC ($94,912) |
All Payment Transactions
613 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 11/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $31.46 | General |
| Category: Cardiology | ||||||
| 11/13/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $138.60 | General |
| Category: Cardiology | ||||||
| 11/06/2024 | IDORSIA PHARMACEUTICALS US INC | Tryvio (Drug) | Education | In-kind items and services | $60.41 | General |
| Category: Hypertension | ||||||
| 11/05/2024 | IDORSIA PHARMACEUTICALS US INC | Tryvio (Drug) | Education | In-kind items and services | $60.41 | General |
| Category: Hypertension | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/07/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Obesity | ||||||
| 10/03/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Not Applicable | ||||||
| 10/02/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,280.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/17/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $26.95 | General |
| Category: Genetic Disease | ||||||
| 08/14/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 08/14/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $467.00 | General |
| Category: Cardiology | ||||||
| 08/07/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Cardiology | ||||||
| 08/01/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,280.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/18/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $27.58 | General |
| Category: Cardiology | ||||||
| 07/10/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Travel and Lodging | In-kind items and services | $793.27 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/10/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/03/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/27/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/25/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $122.94 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/25/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Travel and Lodging | Cash or cash equivalent | $58.60 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/19/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/19/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Travel and Lodging | In-kind items and services | $968.50 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/19/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH INCLISARIN RESEARCH | Novartis Pharmaceuticals Corporation | $8,750 | 1 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $3,137 | 2 |
| Analysis of Accenture?s Predictive Health Intelligence Environment (PHIE) dataset | SANOFI-AVENTIS U.S. LLC | $1,628 | 2 |
| Data were obtained from Accenture?s ?Predictive Health Intelligence Environment? (PHIE) electronic medical record database. | SANOFI-AVENTIS U.S. LLC | $835.00 | 2 |
| Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients with Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia | SANOFI-AVENTIS U.S. LLC | $694.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 1,299 | 2,166 | $553,595 | $158,826 |
| 2022 | 8 | 1,332 | 2,254 | $533,670 | $169,994 |
| 2021 | 12 | 1,453 | 2,421 | $546,620 | $198,651 |
| 2020 | 13 | 1,601 | 2,230 | $554,976 | $180,195 |
Total Patients
5,685
Total Services
9,071
Medicare Billing
$707,666
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 461 | 904 | $248,600 | $84,046 | 33.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 269 | 278 | $190,430 | $42,955 | 22.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 79 | 105 | $36,750 | $14,229 | 38.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 410 | 779 | $54,530 | $8,335 | 15.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $11,550 | $3,896 | 33.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 36 | 56 | $7,280 | $3,504 | 48.1% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 11 | 11 | $4,455 | $1,861 | 41.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 464 | 1,010 | $235,540 | $95,161 | 40.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 276 | 282 | $193,170 | $45,459 | 23.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 56 | 76 | $22,230 | $11,059 | 49.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 414 | 744 | $52,100 | $7,977 | 15.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 36 | 36 | $11,640 | $4,236 | 36.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 59 | $7,670 | $3,173 | 41.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 27 | 27 | $8,550 | $1,555 | 18.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 19 | 20 | $2,770 | $1,374 | 49.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 419 | 937 | $173,345 | $92,982 | 53.6% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 341 | 348 | $238,380 | $58,217 | 24.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 86 | 110 | $28,050 | $15,592 | 55.6% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 399 | 662 | $46,340 | $7,648 | 16.5% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2021 | 14 | 14 | $16,030 | $5,962 | 37.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 39 | 39 | $11,310 | $5,396 | 47.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 48 | 54 | $6,750 | $3,896 | 57.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 26 | 33 | $5,940 | $3,721 | 62.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 43 | 63 | $8,190 | $3,692 | 45.1% |
| 93015 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report | Office | 2021 | 14 | 14 | $6,300 | $708.10 | 11.2% |
About Dr. Dean Karalis, MD
Dr. Dean Karalis, MD is a Cardiovascular Disease healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609849256.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dean Karalis, MD has received a total of $760,521 in payments from pharmaceutical and medical device companies, with $41,912 received in 2024. These payments were reported across 613 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($579,947).
As a Medicare-enrolled provider, Karalis has provided services to 5,685 Medicare beneficiaries, totaling 9,071 services with total Medicare billing of $707,666. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Philadelphia, PA
- Active Since 02/13/2006
- Last Updated 09/13/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1609849256
Products in Payments
- PRALUENT (Drug) $278,722
- PRALUENT ALIROCUMAB INJECTION (Biological) $193,715
- NEXLIZET (Drug) $135,573
- Vascepa (Drug) $47,549
- PRALUENT (Biological) $37,713
- LEQVIO (Drug) $26,655
- NO PRODUCT DISCUSSED (Drug) $13,047
- Repatha (Biological) $12,874
- FARXIGA (Drug) $2,417
- NEXLETOL (Drug) $1,460
- EVKEEZA (Biological) $506.87
- Tryvio (Drug) $120.82
- XARELTO (Drug) $70.15
- AMVUTTRA (Drug) $26.95
- Ozempic (Drug) $24.89
- Arcalyst (Drug) $24.44
- Wegovy (Drug) $23.28
- BRILINTA (Drug) $19.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Philadelphia
Paul Forfia, Md, MD
Cardiovascular Disease — Payments: $1.4M
Cardiovascular Disease $1.4M
Quang Bui, Md, MD
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Anjali Vaidya, Md, MD
Cardiovascular Disease — Payments: $895,146
Cardiovascular Disease $895,146
Ralph Verdino, Md, MD
Cardiovascular Disease — Payments: $683,076
Cardiovascular Disease $683,076
Francis Marchlinski, Md, MD
Cardiovascular Disease — Payments: $456,298
Cardiovascular Disease $456,298
Joshua Cooper, Md, MD
Cardiovascular Disease — Payments: $423,869
Cardiovascular Disease $423,869